Community Portal

A place for Clinicians and Healthcare Suppliers to share knowledge and learn more about THE CLINICIAN EXCHANGE



Provided by: Medscape

Everolimus With Trastuzumab and Paclitaxel for HER2+ MBC

Published: Wed, 13 Dec 2017 12:00:00 EST
Is the combination of everolimus, trastuzumab, and paclitaxel as safe in Asian patients as it is in the overall population?
Breast Cancer Research

Combination of Immunotherapy and Radiation Therapy in NSCLC

Published: Wed, 13 Dec 2017 12:00:00 EST
Review the rationale and preclinical evidence for combining radiation and immunotherapy in NSCLC.
Translational Lung Cancer Research

Binge Drinking and the Risk of Liver Events

Published: Wed, 13 Dec 2017 12:00:00 EST
Does binge drinking increase the risk for liver disease above and beyond the risk due to average alcohol consumption?
Liver International

Pregnancy Outcomes in Obese Women Better With Induced Labor

Published: Tue, 12 Dec 2017 18:14:15 EST
Most differences from expectant management were seen at 39 and 40, but not 41, weeks of gestation.
Medscape Medical News
Displaying results 13-16 (of 20)
 1 - 2 - 3 - 4 - 5 


Denali pulls off 2017’s biggest biotech IPO, pocketing $250M for Parkinson’s, Alzheimer’s trials

Published: Fri, 08 Dec 2017 13:25:01 +0000
Denali Therapeutics has raised $250 million. The IPO, the biggest biotech listing of the year, sets Denali up to push drugs against Alzheimer’s and Parkinson’s diseases through early clinical trials.

Erytech rocked by phase 2b failure in AML

Published: Fri, 08 Dec 2017 12:34:41 +0000
Erytech has delivered a nasty surprise to the investors who backed its IPO last month. The French biotech’s lead candidate failed to improve overall survival in patients with acute myeloid leukemia (AML), wiping 27% off its stock.

Gilead makes bolt-on CAR-T buy after Kite deal

Published: Fri, 08 Dec 2017 09:51:03 +0000
After its $12 billion buyout of Kite this year for its new class of immuno-oncology therapy, Gilead has made a much smaller bolt-on acquisition of Cell Design with an eye to the future of CAR-T.

Amid harassment reports from STAT, Orbimed's Sam Isaly suddenly departs

Published: Fri, 08 Dec 2017 09:21:44 +0000
Orbimed is one of the biggest backers of life science companies in the world with $14 billion in asset management, but today its founder, Sam Isaly, has left the venture capital firm in the same week STAT undertook a damning investigation into his alleged behavior.
Displaying results 13-16 (of 25)
 1 - 2 - 3 - 4 - 5 - 6 - 7 

Clinician Owned and Veteran Owned

copyright 2017 THE CLINICIAN EXCHANGE. Privacy Policy